Maynard Um
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Raised to $50 at Oppenheimer
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on UroGen Pharma (URGN)
-
-
-
-
-
-
-
UroGen publishes 24-month ZUSDURI trial data in Journal of Urology
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Raised to $30 at D. Boral Capital
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Raised to $32 at Guggenheim
-
-
-
-
-
-
-
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Raised to $30 at Guggenheim
-
448,086 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

